Clinical medicine profile
Aceclofenac / Trypsin
NSAID / analgesic–anti-inflammatory
- Route
- ORAL / TOPICAL / RECTAL / IM (agent-dependent)
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- [From component Trypsin / Chymotrypsin] History of allergic reactions to any ingredient of the formulation, severe general infections, peptic ulcer, severe hepatic or renal disease, blood clotting disorders, avoid the use of anticoagulants.and hemorrhagic diathesis.
Precautions
- Lowest effective dose, shortest duration.
- GI protection (PPI) if high risk.
- CV risk (MI/stroke) with many NSAIDs — caution in known CVD.
- Monitor renal function in elderly, diuretic/ACEI/ARB users (triple whammy).
- Avoid combining multiple NSAIDs.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
Dosing is indication-, age-, weight- and organ-function-specific for this INN. Do not use class averages for high-risk patients. Confirm the exact regimen in the current SmPC and Kenya Standard Treatment Guidelines. Typical professional workflow: (1) confirm indication, (2) check renal/hepatic function, (3) screen interactions/allergies, (4) select dose/route/duration, (5) define monitoring.
Paediatric dosing is weight- and age-based; use a paediatric formulary / SmPC. Do not extrapolate adult tablets without calculation.
Haemodynamically mediated AKI risk — high alert in volume depletion and renin-angiotensin blockade.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Rare idiosyncratic hepatitis; more concern with prolonged high doses/diclofenac in some datasets.
Use, effects & interactions
Indications
- Inflammation and pain in rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.
- Clinical selection for Aceclofenac / Trypsin should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: NSAID / analgesic–anti-inflammatory.
- Confirm site-specific dose, duration and monitoring before prescribing.
Adverse effects
- Dyspepsia, nausea, fluid retention, raised BP.
- Serious: peptic ulcer/bleed, AKI, heart failure exacerbation, severe skin reactions, bronchospasm, hepatitis (rare).
Drug interactions
Open multi-drug checker ↗- Fixed-dose/multi-ingredient product.
- Clinical details partially inherited from component monographs: Trypsin / Chymotrypsin.
- Confirm combination SmPC for exact dosing.
Mechanism & disposition
Combination product.
Read complete mechanism
Combination product. Component mechanism (Trypsin / Chymotrypsin): It lowers the intensity of inflammation, reduces the pain, helps in the resolution of edema, and exudate. It also facilitates the penetration of antibacterial agents in the affected areas.
30–60 minutes
4–12 hours (agent-dependent)
ORAL / TOPICAL / RECTAL / IM (agent-dependent)
of metabolites. Half-lives vary widely (ibuprofen short; naproxen longer; oxicams long).
Pregnancy, lactation & diet
[Aceclofenac] Avoid in third trimester. Earlier pregnancy: use only if needed; prefer paracetamol first-line. [Trypsin] Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
[Aceclofenac] Short-course ibuprofen generally acceptable; avoid chronic high-dose/long half-life agents when possible. [Trypsin] Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| Drug interactions: Alcohol | ACE inhibitors | mg / 8mg 10's | Unavailable |
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.